1. |
陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况. 中国肿瘤临床, 2015, 42(13): 668-674.
|
2. |
Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr, 2020, 150(4): 663-671.
|
3. |
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med, 2010, 363(20): 1938-1948.
|
4. |
牟成金, 潘武, 李娟, 等. 干扰 IL-8 表达对乳腺癌细胞侵袭、迁移能力的影响. 免疫学杂志, 2018, 34(9): 765-771.
|
5. |
Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res, 2008, 14(21): 6735-6741.
|
6. |
柴瑛. 骨肉瘤患者白细胞介素 8 表达及其对骨肉瘤细胞增殖、迁移的作用和机制. 中国老年学杂志, 2018, 38(10): 2475-2476.
|
7. |
罗先荣, 彭家清, 熊燕, 等. IL-8 通过下调 miR-199a-3p 对肾癌细胞迁移、侵袭及上皮-间质转化的影响. 免疫学杂志, 2019, 35(12): 1037-1042.
|
8. |
Cheng XS, Li YF, Tan J, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett, 2014, 348(1-2): 77-87.
|
9. |
Sanguinete MMM, Oliveira PH, Martins-Filho A, et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest, 2017, 46(7): 677-688.
|
10. |
杨青, 张香梅, 翁晨刚, 等. 敲低 MDA-MB-231 中 IL-8 的表达影响其增殖和 EMT 过程的相关研究. 第十三届全国免疫学学术大会, 上海, 2018.
|
11. |
朱江, 赵春英, 顾伟, 等. 乳腺癌白介素 8 基因表达及其临床意义. 肿瘤, 2005, 25(4): 386-389.
|
12. |
Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol, 2009, 182(1): 371-378.
|
13. |
Cho EY, Chang MH, Choi YL, et al. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol, 2011, 68(3): 753-761.
|
14. |
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
|
15. |
Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. Lyon: IABC Press, 2012: 13-15.
|
16. |
Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 2010, 11(2): 174-183.
|
17. |
肖培, 叶英楠, 宁俊雅, 等. IL-8 诱导的肿瘤相关巨噬细胞对肝细胞肝癌侵袭转移的影响. 中国肿瘤临床, 2018, 45(2): 55-62.
|
18. |
杨青, 张香梅, 翁晨刚, 等. IL-8 及其受体在肿瘤进展与治疗中的研究进展. 肿瘤防治研究, 2019, 46(1): 81-84.
|
19. |
杨青, 张香梅, 何明, 等. 下调 IL-8 表达抑制食管鳞状细胞癌 KYSE170 细胞的迁移能力及其相关机制. 中国肿瘤生物治疗杂志, 2018, 25(8): 785-790.
|
20. |
方复, 毛华辉, 卢国春, 等. IL-8 在胃癌组织上皮间质转化过程中表达增强. 基础医学与临床, 2019, 39(10): 1444-1448.
|
21. |
Shibakura M, Niiya K, Kiguchi T, et al. Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells. International journal of cancer, 2003, 103(3): 380-386.
|
22. |
Tobin RP, Jordan KR, Kapoor P, et al. IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients. Front Oncol, 2019, 9: 1223.
|
23. |
Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer, 2017, 75: 284-298.
|
24. |
谭敏华, 雷伟华, 胡志雄, 等. 乳腺癌组织中 p53 和 Ki67 蛋白的表达及意义. 广东医学, 2017, 38(S2): 101-104.
|
25. |
Lin Y, Huang R, Chen L, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer, 2004, 109(4): 507-515.
|
26. |
王若珺, 初明, 岑羽捷, 等. 新生淋巴管与乳腺癌淋巴管转移相关性的研究进展. 生理科学进展, 2014, 45(1): 49-54.
|
27. |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
28. |
黄琳, 滕美君, 徐竟男, 等. HIF-1α、ALDH1 和 Hedgehog 信号通路协同促进三阴性乳腺癌中癌症干细胞活化的相关性研究. 中国免疫学杂志, 2017, 33(5): 697-701.
|
29. |
Sharma B, Singh S, Varney ML, et al. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets, 2010, 14(4): 435-442.
|
30. |
Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev, 2017, 60: 24-31.
|
31. |
David JM, Dominguez C, Hamilton DH, et al. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines (Basel), 2016, 4(3): 22.
|
32. |
Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther, 2017, 175: 91-106.
|
33. |
Balacescu O, Balacescu L, Virtic O, et al. Blood genome-wide transcriptional profiles of her2 negative breast cancers patients. Mediators Inflamm, 2016, 2016: 3239167.
|
34. |
Fu XT, Dai Z, Song K, et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol, 2015, 46(2): 587-596.
|
35. |
黄佳欢, 陈俊青, 杨紫烟, 等. PI3K/AKT/mTOR 信号通路在三阴性乳腺癌中的作用及靶向治疗研究进展. 肿瘤学杂志, 2020, 26(9): 784-790.
|
36. |
景文江, 赵新汉, 马武, 等. mTOR 蛋白和 Beclin1 蛋白在三阴性乳腺癌组织中的表达及临床意义. 现代肿瘤医学, 2019, 27(10): 1745-1749.
|
37. |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.
|